Dianthus Therapeutics (DNTH) Current Assets (2017 - 2025)

Dianthus Therapeutics' Current Assets history runs 9 years deep, the most recent figure standing at $409.4 million for Q4 2025.

• On a quarterly basis, Current Assets rose 45.76% year-over-year to $409.4 million in Q4 2025; TTM through Dec 2025 was $409.4 million, a 45.76% increase from a year earlier, with the FY2025 full-year figure at $409.4 million, up 45.76% from the prior year.
• Current Assets eased to $409.4 million in Q4 2025 per DNTH's latest filing, from $413.8 million in the prior quarter.
• Across five years, Current Assets topped out at $413.8 million in Q3 2025 and bottomed at $78.6 million in Q2 2023.
• The 5-year median for Current Assets is $194.0 million (2021), against an average of $222.1 million.
• Across the five-year window, Current Assets sank 54.6% in 2022 and soared 365.03% in 2024, its largest moves.
• Year by year, Current Assets stood at $180.7 million in 2021, then sank by 54.6% to $82.0 million in 2022, then jumped by 116.32% to $177.5 million in 2023, then soared by 58.3% to $280.9 million in 2024, then jumped by 45.76% to $409.4 million in 2025.
• Per Business Quant, the three latest DNTH Current Assets figures stand at $409.4 million (Q4 2025), $413.8 million (Q3 2025), and $263.6 million (Q2 2025).